Media coverage about Allergan (NYSE:AGN) has been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Allergan earned a news impact score of 0.12 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.5008654920961 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the media headlines that may have impacted Accern’s rankings:
- Holcomb – Kreithen Plastic Surgery and MedSpa is Now Holcomb – Kreithen Plastic Surgery and Dermatology, Adding a Dermatologist to the Ever Growing Medical Practice (prweb.com)
- Allergan plc (AGN) Director Buys $129,078.00 in Stock (americanbankingnews.com)
- Allergan plc (AGN) projected to achieve earnings growth of -543.10% for this year – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Allergan plc (AGN) has analyst mean rating score of 2.10 – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Why Is Allergan (AGN) Down 10.1% Since its Last Earnings Report? (finance.yahoo.com)
Allergan (NYSE AGN) traded up $4.78 during trading on Tuesday, reaching $163.19. 4,330,708 shares of the company were exchanged, compared to its average volume of 3,850,000. The company has a market capitalization of $55,180.00, a P/E ratio of -13.61, a P/E/G ratio of 1.11 and a beta of 1.29. Allergan has a 1-year low of $142.81 and a 1-year high of $256.80. The company has a current ratio of 1.16, a quick ratio of 1.06 and a debt-to-equity ratio of 0.38.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 28th. Investors of record on Wednesday, February 28th will be given a $0.72 dividend. The ex-dividend date is Tuesday, February 27th. This represents a $2.88 dividend on an annualized basis and a yield of 1.76%. This is an increase from Allergan’s previous quarterly dividend of $0.70. Allergan’s dividend payout ratio (DPR) is -24.02%.
AGN has been the topic of several analyst reports. Royal Bank of Canada set a $218.00 target price on shares of Allergan and gave the stock a “buy” rating in a report on Thursday, January 4th. Credit Suisse Group set a $214.00 target price on shares of Allergan and gave the stock a “buy” rating in a report on Tuesday, December 19th. They noted that the move was a valuation call. Vetr lowered shares of Allergan from a “strong-buy” rating to a “buy” rating and set a $187.73 target price on the stock. in a report on Wednesday, December 6th. Morgan Stanley set a $200.00 target price on shares of Allergan and gave the stock a “buy” rating in a report on Wednesday, December 6th. Finally, Wells Fargo & Co reiterated a “buy” rating on shares of Allergan in a report on Wednesday, December 6th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $225.03.
In other Allergan news, CFO Matthew M. Walsh bought 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 21st. The stock was acquired at an average price of $160.94 per share, with a total value of $321,880.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider William Meury sold 58,879 shares of the firm’s stock in a transaction on Wednesday, February 14th. The shares were sold at an average price of $160.62, for a total transaction of $9,457,144.98. The disclosure for this sale can be found here. In the last ninety days, insiders purchased 7,200 shares of company stock valued at $1,108,267. 0.36% of the stock is owned by insiders.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.